REATMENTS such as surgery, radiation, and chemotherapy have not improved the prognosis in patients with malignant glioma during the last few years. It is therefore important to develop novel therapies for these brain tumors. The CNS is immunologically privileged because it lacks lymphoid reactivity and normal immune surveillance. Recently, investigators from several groups have reported immunotherapy protocols in which intradermal vaccines consisting of genetically modified tumor cells were used effectively in brain tumor models in rodents.
The DCs are rare, hematopoietically derived leukocytes that form a cellular network involved in immune surveillance, antigen capture, and antigen presentation, 18, 19 although tumor cells themselves are poor antigen-presenting cells. It has now become clear that DCs may play an important supporting role in promoting and maintaining antigen-specific T cells in vivo. The DCs are potent stimulators of naive T cells. This function of DCs results from their expression of important costimulatory molecules, their residence in both lymphoid and nonlymphoid tissues, their ability to migrate from sites of antigen entry to lymphoid organs, and their efficient processing and presentation of a wide variety of antigens. Immunization in which DCs loaded with tumor antigens are used represents a powerful method for inducing antitumor immunity. In recent studies it has been shown that immunizing mice with DCs pulsed with specific antigens can prime a CTL response that is tumor-specific and confers protective tumor immunity in the treated mice. 4, 15 Many strategies for delivering antigens into DCs have been established in murine models, and these are now undergoing evaluation in clinical trials. These strategies include the use of synthetic peptides when the tumor antigen is known, 4, 11, 15 stripped peptides derived from Class I molecules in murine tumors, 23 use of tumor RNA, 3 or tumor lysates. 2 The advantages of vaccinating with totally tumor-derived material are that the identity of the tumor antigens need not be known and that the presence of multiple tumor antigens reduces the risk of antigen-negative escape mutants. It is now clear that tumors of diverse histological origins and causes are susceptible to therapies based on DCs. 
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Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki Forest virus-mediated complementary DNA Viral vectors commonly used for therapeutic DNA delivery include replication-deficient forms of adenovirus, retrovirus, and herpes simplex virus. Although retroviruses have the advantage of mediating stable gene transfer with a low potential for immunogenicity, this vector delivery system has some problems related to therapeutic use. These include difficulties in producing high titers of retrovirus, the fact that only actively dividing cells are capable of being infected, and the possibility of insertional mutagenesis. 12 The adenovirus vector system, although capable of delivering genes with high efficiency to a wide spectrum of nondividing cells in vivo, 6 has unfortunately produced only transient expression with different gene products. Transient expression may result from a strong immune response of host cells against the adenovirus. However, SFV, a member of the Alphavirus genus, has received considerable attention for use as a virus-based expression vector. The SFV expression system differs from currently available viral delivery systems in that it is an RNA virus; these are known to generate high levels of protein expression in vitro. Also, SFV is less pathogenic 14 to humans. The self-amplifying expression vector SFV is capable of producing high-titer stocks of infectious particles, as well as infection of nondividing cells and the generation of high-level expression of transgenes. 20 In experiments presented here we evaluated the efficacy of genetically modified DCs pulsed with SFV-mediated tumor cDNA. The vaccines were studied in a model of active immunotherapy for CNS tumors.
Materials and Methods

Tumor Cell Lines and Animal Models
The 203 glioma cell line, which was derived from a glioma in a C57BL/6 mouse, and the B16/F10 murine melanoma cell line were the principal ones used in this study. (The B16/F10 murine melanoma cell line was chosen as a control for the 203 glioma.) We also used BHK cells for cotransfections. Cell lines were grown in MEM containing 10% FCS. All cell lines were shown to be free from mycoplasma contamination. In all experiments 6-to 12-week-old female C57BL/6 mice were used; the animals were maintained in a virus-free environment and treated in accordance with the National Institutes of Health Laboratory Animal Resources Commission standards.
Generation of DCs From Bone Marrow Cultures
The procedure used in these studies was similar to that previously described. 2 In brief, bone marrow was flushed from the femoral bones and depleted of red cells with ammonium chloride. Bone marrow cells were depleted of lymphocytes, granulocytes, and Ia cells by using a mixture of MAbs and complement. The MAbs used were 2.43 (CD8), GK1.5 (CD4), RA3-3A1/6.1 (CD45R), B21-2 anti-Ia (Tumor Immunology Bank Nos. 210, 207, 146, and 229, respectively) and RB6-8C5 anti-Gr-1. Cells were plated in six-well culture plates (10 6 cells/ml, 3 ml/well) in RPMI 1640 medium supplemented with 5% heat-inactivated FCS, 50 mM 2-mercaptoethanol, 10 mM HEPES (pH 7.4), 2 mM glutamine, 100 U/ml penicillin, 100 mg/ ml streptomycin, 3.3 ng/ml granulocyte-macrophage colony-stimulating factor, and 1000 IU/ml interleukin-4. On Day 3 of culture, floating cells were gently removed. On Day 7 of culture, nonadherent cells and loosely adherent proliferating DC aggregates were collected and replated. On day 10 of culture, nonadherent cells (that is, DCs) were removed for analysis and used in immunizations. The quality of DC preparation was characterized by cell surface markers and morphological analysis. For phenotypic analysis, FITC-conjugated MAbs against murine cell surface molecules , and appropriate isotype controls) were used, and cytometric analysis was performed using an FACS.
Generation of SFV Particles
The plasmid pSFV3, pSFV3-LacZ, contains an SP6 promoter, a 7-kb fragment encoding the SFV RNA replicase, and a subgenomic promoter that is bound by the RNA replicase to synthesize large quantities of subgenomic RNA (Fig. 1) . A helper plasmid pSFVHelper 2, which contains the genes for the structural proteins (capsid, E3, E2, 6K, and E1) required for packaging the viral genome, was used for construction of the recombinant envelope gene. The SFV-cDNA was constructed as follows: briefly, cDNA was synthesized from the messenger RNA of 203 glioma or B16 by using a cDNA synthesis kit. The cDNA was put into pSFV by using BamHI and SmaI adaptors. The plasmid pSFV-EGFP was constructed by replacing the LacZ fragment in pSFV-LacZ with the EGFP fragment from the plasmid pEGFP-C1. Helper plasmid and expression plasmids (pSFV3-LacZ, pSFV3-cDNA) were linearized by Spe I restriction enzyme digestion. The Spe I was used to linearize DNA templates for the synthesis of SFV-cDNA RNA. The SFV-cDNA RNA was transcribed in vitro and capped using SP6 RNA polymerase and capping analog. The BHK cells and DCs were transfected with SFV-cDNA RNA and helper virus RNA, respectively. For cotransfections of helper and expression RNA into BHK cells, electroporation was performed. Electroporated cells were transferred to 10 ml of MEM containing 5% FCS and incubated for 12 hours. Cells were then washed with PBS and incubated in 10 ml of MEM without FCS. After 24 hours, culture supernatants were harvested and aliquots were stored at Ϫ80˚C. Recombinant SFV particles were produced, and infectivity of recombinant viruses to BHK cells and DCs was determined by transfer of the SFV vector that can transduce the ␤-galactosidase gene. Viral supernatant dilutions were added to adherent cells (2 ϫ 10 5 ) in six-well plates. After 1 hour of incubation at 37˚C, cells were washed with PBS and incubated in growth medium at 37˚C for 24 hours. Viral infection was evaluated by X-gal staining. Briefly, cells were fixed in PBS containing 0.5% glutaraldehyde for 15 minutes followed by washing three times with PBS. Cells were then stained with PBS containing 1 mg/ml X-gal, 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 1 mM MgSO 4 at 37˚C for 2 hours.
In Vitro Cytotoxicity Assay
In vitro cell-mediated cytotoxicity assays were performed using standard procedures, as previously described. 21 In this study, splenocytes obtained from immunized animals and controls were restimulated in vitro for 5 days on monolayers of mitomycin C-treated 203 glioma or B16 cells. Target cells included 203 glioma or B16 cells.
Implantation of Brain Tumors
The 203 glioma cells or B16 cells were harvested by trypsinization, and washed twice in Dulbecco's PBS. The cells (500 cells in a volume of 5 L) were then implanted into the right caudate nucleus of the brain of C57BL/6 mice by stereotactic injection as previously described. 21 The treated animals were examined macro-and microscopically. Intratumor cells were evaluated using anti-CD8 antibody (Ly-2) and FITC-labeled anti-rat immunoglobulin G.
Cell Death and Uptake Analysis
The cell death and uptake analysis was performed as described elsewhere. 22 Briefly, the self-replicating SFV was transcribed in vitro from the pSFV-EGFP plasmid, then transfected into DCs. As a control, the plasmid pEGFP-C1 was also transfected into DCs. The green fluorescent protein-positive (green) and -negative cells were sorted and plated into 48-well plates (500 cells/well, 10 wells/ group) and then viable cells were counted every 24 hours. Also, DNA fragmentation, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay, and caspase activity were investigated to confirm the apoptosis. In uptake experiments, DCs were transfected with SFV-EGFP, then labeled 24 hours later with PKH26-GL. Labeled cells (10 6 ) were co-cultured with 10 6 bone marrow-derived immature DCs prepared by cultur-ing bone marrow cells for 4 days. Cells were then stained with FITC-labeled anti-I-A b MAb and analyzed using FACS.
Statistical Analysis
Survival estimates and median survival times were determined using the method of Kaplan and Meier. Survival data were compared using the Wilcoxon test. The Student t-test was used for calculating the significance of other data. Statistical significance was determined at probability levels of less than 0.05.
Sources of Supplies and Equipment
The 203 glioma and B16/F10 cell lines were kindly provided by Riken Cell Bank, Tsukuba, Japan. The BHK cells were obtained from Invitrogen, San Diego, CA. The Opti-MEM was acquired from Gibco-BRL, Gaithersburg, MD. The C57BL/6 mice were purchased from Jackson Laboratory, Bar Harbor, ME.
The MAbs used for depletion of lymphocytes, granulocytces, and Ia cells in bone marrow were obtained from the American Type Culture Collection, Bethesda, MD, with the exception of RB6-8C5 anti-Gr-1, which was obtained from DNAX, Palo Alto, CA. The interleukin-4 was provided by Amgen, Inc., Thousand Oaks, CA. The MAbs used for phenotypic analysis and their isotype controls were acquired from PharMingen, La Jolla, CA, as were the anti-CD8 antibody, the anti-rat immunoglobulin G, and the anti-I-A b . The FACScan was purchased from Becton-Dickinson, San Jose, CA. The cDNA synthesis kit was obtained from Pharmacia, Piscataway, NJ. The pEGFP-C1 was acquired from Clontech, Palo Alto, CA. The plasmid pSFV3, pSFV3-LacZ, and the SP6 RNA polymerase and capping analog were purchased from Life Technologies, Grand Island, NY. The PKH26-GL was obtained from Sigma Chemical Co., St. Louis, MO.
Results
Generation of DCs and Infection With Recombinant Viruses
After 7 days of culture, DC aggregates were seen, and these cells were found to be positive for MHC Class I, MHC Class II, CD80 and CD86 (Fig. 2) . Infectivities of recombinant viruses were determined by transfer of the pSFV-LacZ that can transduce the ␤-galactosidase gene. Viruses had a very high infection titer against BHK cells (5 ϫ 10 7 LacZ colony-forming units/ml) and DCs (10 7 LacZ colony-forming units/ml).
Vaccination With Bone Marrow-Derived DCs Pulsed With Tumor cDNA Induces Tumor-Specific CTLs
To test whether bone marrow-derived DCs pulsed with SFV-mediated tumor cDNA can induce tumor-specific CTLs, we first immunized C57BL/6 mice with three intraperitoneal injections of DCs spaced 1 week apart. Standard cytotoxicity assays were performed using splenocytes harvested from immunized animals 7 days after the third immunization and restimulated for 5 days in vitro with irradiated 203 glioma cells or B16 cells. Cytotoxic activity was tested against 203 (Fig. 3A) or B16 cells ( cant compared with animals immunized using DCs pulsed with 203 glioma RNA, lysate, SFV-LacZ, or SFV-mediated B16 cDNA, or compared with animals injected with PBS (p Ͻ 0.01). Also, immunization with DCs pulsed with SFV-mediated B16 cDNA induced B16-specific CTL responses that were statistically significant compared with animals immunized using DCs pulsed with B16 RNA, lysate, SFV-LacZ, or SFV-mediated 203 glioma cDNA, or compared with animals injected with PBS (p Ͻ 0.01). We have shown that the specificity of 203 glioma cDNA is more effective for 203 glioma and less for B16, and that the reverse condition also applies.
Tumor Challenge in CNS After Immunization With DCs Pulsed With Tumor cDNA
Experiments were performed to determine whether vaccinations in which DCs pulsed with SFV-mediated tumor cDNA were used generated protective immunity against the tumor within the CNS. Groups of C57BL/6 mice received three intraperitoneal vaccinations spaced 1 week apart and composed of DCs pulsed with PBS, 203 glioma lysate, RNA, B16 lysate, or with SFV-LacZ, SFV-mediated B16 cDNA, or with SFV-mediated 203 glioma cDNA. One week later mice were challenged with 500 viable 203 glioma (Fig. 4A ) or B16 cells (Fig. 4B ) injected into the brain. As shown in Fig. 4A , immunization with DCs pulsed with PBS, 203 glioma lysate, RNA, SFV-LacZ, or SFV-mediated B16 cDNA did not protect the animals against CNS challenge with 203 glioma cells. All animals in these groups died of this tumor; the median survival time was between 35 and 40 days. In contrast, the median survival of animals that underwent vaccination with DCs pulsed with SFV-mediated 203 glioma cDNA was significantly prolonged, to more than 90 days (p Ͻ 0.05), with seven of 14 animals alive when the experiment was stopped at 90 days. Also, as shown in Fig. 4B , immunization with DCs pulsed with PBS, B16 lysate, B16 RNA, SFV-LacZ, or SFV-mediated 203 glioma cDNA did not protect against CNS challenge with B16 cells. All animals in these groups died of the tumor; the median survival time was between 35 and 48 days. In contrast, the median survival time of animals that underwent vaccination with DCs pulsed with SFV-mediated B16 cDNA was significantly prolonged to greater than 90 days (p Ͻ 0.05), with seven of 14 animals still alive when the experiment was stopped at 90 days. We have shown that the specificity of 203 glioma cDNA was better for 203 glioma and less for B16 cells, and that the reverse condition also applied.
Prolonged Survival of Mice With CNS Tumors Treated With DCs Pulsed With SFV-Mediated cDNA
In considering the clinical application of a tumor vaccination strategy, it is more realistic to treat animals in which tumors are present at the time of vaccination. Thus, in the next experiment, 500 viable 203 glioma cells (Fig.  5A ) or B16 cells (Fig. 5B) were implanted in the brains of naive mice, and treatment of these mice started 4 days later. The results are reported according to the animals' survival times, as follows. Animals treated with DCs pulsed with PBS, 203 glioma lysate, B16 or 203 glioma RNA, SFV-LacZ, or SFV-mediated B16 cDNA in three intraperitoneal vacinations spaced 1 week apart had median survivals time ranging from 20 to 35 days. Mice treated with DCs pulsed with SFV-mediated 203 glioma cDNA had a significantly longer median survival time of 90 days (p Ͻ 0.05); seven of 14 animals were alive at 90 days when the experiment was stopped (Fig. 5A ). Animals treated with DCs pulsed with PBS, B16 lysate, B16 or 203 glioma RNA, SFV-LacZ, or SFV-mediated 203 glioma cDNA in three intraperitoneal vaccinations spaced 1 week apart had median survival times ranging from 20 to 38 days. Mice treated with DCs pulsed with SFV-mediated B16 cDNA had a significantly longer median survival time of 90 days (p Ͻ 0.05); seven of 12 animals were alive at 90 days when the experiment was stopped (Fig. 5B) . We have also shown that the specificity of 203 glioma cDNA was bettter for 203 glioma and less for B16 cells, and that the reverse condition applied as well.
Intratumoral Infiltration of CD8 T Cells in Mice Treated With DCs Pulsed With SFV-Mediated cDNA
The brains of the animals treated with DCs pulsed with SFV-mediated cDNA of tumor cells that survived more than 90 days revealed no evidence of tumor, indicating eradication of established lesions in these long-term survivors (Fig. 6A ). In addition, there was no evidence of chronic inflammation in the brains of the animals (data not shown). Immunohistochemical analysis of tissue obtained in mice treated with DCs pulsed with SFV-mediated 203 glioma cDNA showed an increased intratumoral infiltration of CD8 T cells (Fig. 6C ). This indicates that there was a CTL response in vivo.
Apoptosis After Transfection With SFV and Uptake of SFV-Induced Apoptotic Cells by DCs
After being transfected with SFV-EGFP, cells rounded up, began to shrink, and stopped dividing after 24 hours. At 48 hours, these cells had nuclear fragmentation characteristic of apoptosis. Results of the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling assay and caspase activity findings were also characteristic of apoptosis (data not shown). Nearly all of the cells died by 96 hours. The proliferation of DCs transfected with a conventional DNA plasmid encoding EGFP remained similar to that of nontransfected control cells (Fig. 7A) . In uptake experiments, PKH (red) and I-A b (green) cells were evaluated at 3 and 24 hours by using FACS analysis. Double-positive cells were counted as a fraction of total FACS events. The uptake of SFV-induced apoptotic cells by DCs was also evident (Fig. 7B) .
Discussion
In this study we have shown that a vaccine strategy prolonged the survival of tumor-bearing animals, probably by inducing a CTL response. The treatment of tumor-bearing mice with DCs pulsed with SFV-cDNA derived from the same type of tumor cells led to a dramatic reduction in the mortality rate at 90 days. At that time, more than 50% of the treated animals were still alive, and histological analysis indicated that SFV-cDNA DC therapy led to the eradication of established tumors in the long-term survivors. We have shown that this therapy could be used for both protection against CNS tumor challenge and in the treatment of established tumors. Interestingly, DCs pulsed with SFV-mediated B16 cDNA appeared to be as effica-
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Dendritic cell-based immunotherapy for malignant glioma cious as DCs pulsed with 203 glioma RNA or 203 glioma lysate, and also DCs pulsed with SFV-mediated 203 glioma cDNA appeared to be as efficacious as DCs pulsed with B16 RNA or B16 lysate. This may be related to the overlapping of some tumor antigens between 203 glioma and B16 cells. Furthermore, we showed that the specificity of 203 glioma cDNA was better both in vitro and in vivo for 203 glioma and worse for B16 cells, and that the reverse also applied.
Only three other studies of DC-based therapy for CNS tumors have been published previously. In the first tumor extracts and RNA were used to pulse DCs, 2 in the second a synthetic viral peptide was used to induce an antitumor response, 13 and in the third acid-eluted surface peptides were used. 10 We have tried to treat patients with malignant glioma by using a vaccination protocol in which DCs pulsed with autologous tumor lysate were used. At this stage, however we have not been able to obtain sufficient results (unpublished data). Therefore, we have conducted further investigations to develop effective immunotherapy protocols in which DCs are used. The novelty of our study lies in the use of SFV based on a cDNA vaccine.
Although some genes encoding tumor antigens recognized by CD8 T cells have recently been cloned, the CNS tumors express epitopes that are as yet undefined. Without a specific tumor antigen for human gliomas, a single peptide may not be effective in the clinical setting. It has been suggested that antitumor T-cell response may require a broad spectrum of epitopes rather than a single tumor epitope. 11 If this is the case, use of SFV-cDNA may be a better strategy for obtaining epitopes than single-antigen approaches.
Semliki Forest virus is being developed as a vector for expression of heterologous genes and it has many advantages. In SFV systems, because helper RNA does not contain a packaging signal, it will not form a defective interfering particle or be packaged with recombinant RNA. Furthermore, replication occurs entirely in the cytoplasm of the infected cells as an RNA molecule, without a DNA intermediate. 20 This is in contrast with retroviruses, which must enter the nucleus and integrate into the host genome to initiate vector activity. Thus, retrovirus vectors have applications for long-term expression of foreign genes, whereas SFV vectors are useful primarily for transient high-level expression. Furthermore, although adenovirus vectors can express high levels of foreign genes, these systems are more complex than SFV and express many highly antigenic virus-specific gene products, including structural proteins. 16 In contrast, currently SFV expresses only the four viral replicase proteins (nsP1-4) required for RNA amplification in the transduced cells. The self-replicating RNA produced more than 200% the amount of antigen produced by a conventional DNA immunogen. 22 This system has been found to express significant quantities of heterologous proteins in vitro 8 and in vivo. 14 Given the observations described here, one of the mechanisms underlying the enhanced immunogenicity of SFV-cDNA vaccines may be the efficient amplification of tumor antigens that are presented on the MHC molecules in DCs. As we have shown, DCs acquire antigen from other apoptotic DCs for further presentation to T cells. 1, 22 Furthermore, SFV induced apoptosis in infected cells. 9, 22 Thus, it is possible that both activation and apoptosis, which are induced in DCs on SFV-cDNA infection, play an important syngeneic role in the initiation of specific immune responses against tumor cells. The other mechanisms underlying the enhanced immunogenicity are increased uptake of antigen by DCs and other specialized antigen-presenting cells that die apoptotically as a result of the replicase activity. Thus, the self-replicating SFV system could serve as a powerful tool for treating malignant brain tumors.
Conclusions
This protocol, in which DCs pulsed with SFV-mediated tumor cell cDNA were used to treat experimental brain tumors, showed prolongation of survival in tumor-bearing animals and induction of a CTL response. Thus, the self-replicating SFV system may open novel approaches for the treatment of malignant glioma.
